Pharmacogenetic program innovation — now supporting the benefits ecosystem

Dr. Siminovitch is an internationally recognized clinician-scientist, rheumatologist and leader in genomic and precision medicine. A Professor of Medicine and Immunology at the University of Toronto and a senior investigator at Sinai Health’s Lunenfeld-Tanenbaum Research Institute, she has spent more than four decades investigating the genetic and molecular mechanisms underlying immune dysfunction. Her landmark contributions include mapping the gene responsible for Wiskott-Aldrich syndrome and identifying important genetic risk factors and biological pathways associated with rheumatoid arthritis, Crohn’s disease, vasculitis and other autoimmune conditions. Her work has advanced the understanding of immunological disease while supporting the development of more precise diagnostic tools and individualized therapies.

Dr. Siminovitch has also founded and led major programs that translate genomic discovery into patient care, including the Fred A. Litwin Family Centre in Genetic Medicine, the Mount Sinai Hospital - University Health Network Clinical Genomics Centre, a Centre of Excellence in Precision Medicine in Autoimmune Disease and the University of Toronto’s Clinician-Scientist Training Program. As the founding scientist of Inagene, she has helped bring evidence-based pharmacogenetic testing and personalized medicine into more accessible, everyday health care.

A Fellow of both the Royal Society of Canada and the Canadian Academy of Health Sciences, Dr. Siminovitch received the University of Toronto Temerty Faculty of Medicine’s Dean’s Alumni Lifetime Achievement Award in 2026. Beyond medicine, she co-founded and helped sustain the Siminovitch Prize in Theatre, reflecting a career-long commitment to excellence, innovation and public contribution across science, health care, education and the arts.

Alan Greenberg brings decades of leadership experience in real estate, venture capital, and technology-driven innovation. A seasoned investor and entrepreneur, Alan is the Founder and CEO of Minett Capital and Co-Founder and Chair of GreenSoil Investments, where he has focused on advancing transformative technologies in proptech, agtech, climate tech, and healthcare. Prior to his investment career, he spent nearly 30 years with The Minto Group, culminating as President and COO of Minto Urban Communities, where he helped establish the company as a North American leader in sustainable development and urban design. As a strong advocate for precision medicine, Alan co-founded Inagene based on his belief that personalized healthcare and pharmacogenetics will play a critical role in improving patient outcomes and transforming the future of medication management.

Peter Lowas brings two decades of leadership experience across financial services and health to his role as Chief Executive Officer of Inagene Diagnostics. His career has spanned senior roles in strategy, product, digital, and customer experience at some of Canada's most recognized organizations including Manulife's Group Benefits division and Shoppers Drug Mart Health & Wellness and Specialty Drug divisions. Peter's expertise is at the intersection of health, benefits, and commercial strategy, building a deep understanding of how employers and insurers make decisions.

Peter joined Inagene with a belief that pharmacogenetics is one of the most underutilized tools in Canadian healthcare today. He is focused on bringing precision medicine out of the clinic and into the hands of everyday Canadians, either directly or through their benefit plan sponsors, disability managers, and healthcare providers.

Benjamin Pinder, PhD, is Inagene’s Scientific Director. Since joining Inagene Diagnostics in 2018, he has helped guide the scientific development and delivery of the company’s pharmacogenomic testing services. He oversees laboratory operations and works to ensure that Inagene’s testing remains scientifically rigorous, clinically relevant, and informed by current advances in genomic medicine.

Dr. Pinder has extensive experience in genetics, genomics, pharmacogenomics, and clinical laboratory testing. He is a founding member of the Pharmacogenomics Global Research Network and has contributed to research on heritable autoimmune diseases, developmental biology, gene regulation, and the genetic factors that influence drug response.

Philip Rees owns commercial growth, product, and engineering at Inagene. His experience spans scientific research, engineering, and leadership, with a career built on scaling products and teams from launch to lasting revenue.

Previously he was a founding employee and Chief Technology Officer at Tidal Cloud, a Toronto-based software company, where he built and led the product engineering teams behind its products and helped grow it into one of Canada's fastest-growing companies.

Philip holds a BSc in Genetics from Western University. His earlier work in drug discovery produced several patents and peer-reviewed publications. He received the Best Executive Award in Technology in 2023.

Ashwin earned both his BScPhm and PharmD from the University of Toronto and an MBA from Queen’s University. Before joining Inagene, he gained significant experience as a clinically oriented community pharmacist and pharmacy manager. He has helped lead a local pharmacist committee, presented at pharmacy conferences, and served as a guest interviewee, panelist, and judge across media and professional forums. He has also served as a peer reviewer, authored scientific publications, and contributes occasionally to Pharmacy Practice+Business magazine online. He is a passionate advocate for pharmacogenetics and healthcare innovation more broadly.

Carrie Anne leads the company’s B2B growth strategy and builds relationships across the benefits, healthcare, and employer ecosystems. With more than 15 years of experience in healthcare business development, partnership management, and go-to-market strategy, Carrie Anne has held leadership roles with TELUS Health, Best Doctors, and Teladoc Health. Passionate about improving access to quality healthcare, she works closely with consultants, plan sponsors, providers, and healthcare organizations to integrate pharmacogenetics into benefit plan design, helping drive better health outcomes, reduce medication trial-and-error, and improve plan sustainability.

Suzanne Laughton leads brand strategy, growth marketing, and customer engagement initiatives that help make personalized medicine more accessible and understandable. With more than a decade of experience in brand development and integrated marketing, Suzanne has built and scaled brands across healthcare, retail, e-commerce, and consumer packaged goods, including leadership roles at Knix, Roots, and Moosehead Breweries. Known for translating complex concepts into compelling customer experiences, she combines data-driven strategy with creative storytelling to drive growth, strengthen brand awareness, and position Inagene as a leader in precision health and pharmacogenetics.